Clinical Trial Update: A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating HLX43, an anti-PD-L1 antibody-drug conjugate, for advanced gynecologic cancers; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Ovarian Cancer

Drugs mentioned

• HLX43

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Cervical Cancer, Ovarian Cancer | Phase 2 | Status: RECRUITING